Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DNTH Dianthus Therapeutics PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: DNTH
- PE Ratio
The current P/E ratio of DNTH cannot be calculated, as the latest EPS of -$2.89 is negative. The most recent PE ratio recorded for Dianthus Therapeutics was 3.82 in September 2024.
DNTH PE ratio history
How has DNTH's PE ratio performed in the past
Today
N/A
Average
N/A
Median
N/A
Minimum
N/A
Maximum
N/A
Dianthus Therapeutics PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $21.8 | -$2.55 |
| 2023 | N/A | N/A | $10.4 | -$8.45 |
| 2022 | N/A | N/A | $6.32 | -$32.57 |
| 2021 | N/A | N/A | $70.88 | -$20.64 |
| 2020 | N/A | N/A | $125.44 | -$27.36 |
| 2019 | N/A | N/A | $242.56 | -$33.12 |
| 2018 | N/A | N/A | $91.2 | -$50.08 |
| 2017 | N/A | N/A | N/A | -$305.92 |
| 2016 | N/A | N/A | N/A | -$1,042.4 |
Dianthus Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | N/A | N/A | $18.14 | -$2.89 |
| Dec 2024 | N/A | N/A | $21.8 | -$2.55 |
| Sep 2024 | 3.82 | -39.17% | $27.38 | $7.16 |
| Jun 2024 | 6.28 | N/A | $25.88 | $4.12 |
| Mar 2024 | N/A | N/A | $30 | -$8.1 |
| Dec 2023 | N/A | N/A | $10.4 | -$8.45 |
| Sep 2023 | N/A | N/A | $13.67 | -$36.18 |
| Jun 2023 | N/A | N/A | $12.13 | -$41.3 |
| Mar 2023 | N/A | N/A | $12.72 | -$33.21 |
| Dec 2022 | N/A | N/A | $6.32 | -$32.57 |
| Sep 2022 | N/A | N/A | $22.56 | -$24.9 |
| Jun 2022 | N/A | N/A | $19.2 | -$20.8 |
| Mar 2022 | N/A | N/A | $46.4 | -$21.28 |
| Dec 2021 | N/A | N/A | $70.88 | -$20.64 |
| Sep 2021 | N/A | N/A | $116.48 | -$21.6 |
DNTH Price vs fair value
How does DNTH's price compare to its estimated fair value based on its growth
DNTH average PE ratio chart
What is the average PE ratio of DNTH for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
N/A
15-year avg
N/A
DNTH PE vs peers
What is DNTH's PE ratio compared to its peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| OLMA Olema Pharmaceuticals Inc | N/A | $288.74M |
| OMER Omeros Corp | N/A | $195.7M |
| VIVS VivoSim Labs Inc. | N/A | $2.66M |
| ORIC Oric Pharmaceuticals Inc | N/A | $645.48M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $93.14M |
| DNTH Dianthus Therapeutics Inc | N/A | $577.59M |
Frequently asked questions
What is Dianthus Therapeutics's PE ratio?
The current price to earnings ratio of DNTH cannot be determined, as its EPS of -$2.89 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.